Valneva Shares Plunge 7%, Downgraded to 'Sell' by Goldman Sachs
Shares of the Nantes-based vaccine specialist Valneva experienced a sharp decline this Wednesday, falling below €2.41 in mid-afternoon. This drop occurs in an already deteriorated context for the stock, which has lost nearly 43% over the past three months.
The main catalyst for the session is the revision published on April 22 by Goldman Sachs, which downgraded its recommendation on Valneva from 'neutral' to 'sell', while also lowering its price target from €3.25 to €2.15. This new target is approximately 11% below the current price of €2.41, suggesting further downside potential according to the American bank. Goldman Sachs' decision weighs heavily on the stock, which is down 7.1% compared to the previous day's close (€2.59). Over the past week, Valneva has lost nearly 9%. The next financial event to watch will be the publication of the first-quarter results, scheduled for May 7, followed by the annual general meeting on June 1.
Technical Analysis of the Stock
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
From a technical standpoint, the stock's configuration remains particularly tense. The price of €2.41 is now below the lower Bollinger Band (€2.50), a signal usually associated with an oversold condition. The RSI at 31 confirms this reading by nearing the conventional threshold of 30, territory generally considered as oversold. Furthermore, the stock is trading well below its 50-day (€3.84) and 200-day (€3.89) moving averages, indicating a firmly established downward trend. The technical support identified at €2.55 has already been breached during the session, potentially paving the way for further tensions. On the broader markets, the CAC 40 is down 0.39% at 8,203 points in a generally cautious environment. Among comparable pharmaceutical sector stocks, Sanofi remains stable (+0.09%) while UCB is down 1.74%. Across the Atlantic, major names like Eli Lilly and Johnson & Johnson also showed declines at the day's close.
Au troisième trimestre, nous avons continué à nous concentrer sur le renforcement de notre trésorerie, ce qui nous a permis de refinancer notre dette à des conditions financières plus avantageuses.
Chiffre d’affaires de 127,0 millions d’euros sur neuf mois (+8,9 %), ventes de 119,4 millions d’euros, trésorerie de 143,5 millions d’euros au 30/09/2025, perte nette 65,2 millions d’euros, EBITDA ajusté (37,7) millions d’euros. Guidance 2025 confirmée : chiffre d’affaires attendu entre 165 et 180 millions d’euros; ventes attendues entre 155 et 170 millions d'euros. Renforcement de la position financière via refinancement et ATMs; Phase 3 VALOR pour le vaccin Lyme en cours selon calendrier.
Risks mentioned
Suspension de la licence IXCHIQ ® aux États-Unis par la FDA (impact sur ventes segment voyageurs)
Risque de résultats cliniques défavorables pour les candidats (phase 3 VALOR pour Lyme, essais S4V2, VLA1601 incertitudes réglementaires)
Exposition aux fluctuations de change (impact négatif mentionné de 1,3 millions d’euros sur ventes, effets de change volontaires)
Dépendance à des partenaires de distribution et diminution des produits de tiers (arrêt de distribution de Rabipur/RabAvert et Encepur)
Opportunities identified
Résultats positifs potentiels de la Phase 3 VALOR (VLA15) pouvant mener à des demandes d'autorisation en 2026
Accord commercial avec CSL Seqirus en Allemagne pour stimuler la commercialisation des vaccins
Croissance des ventes d'IXCHIQ ® sur les marchés hors États-Unis et dans les PRFI (livraisons de substance active)
Potentiel du candidat S4V2 contre la shigellose (marché estimé > 500 millions de dollars/an)
Données positives de Phase 1 pour VLA1601 (Zika) et forte persistance d'anticorps pour IXCHIQ ® (95 % à 4 ans) comme avantage concurrentiel
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
